The present invention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety comprising prostaglandin analogues. The present invention also relates to methods for preparing the polymer conjugates using click chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the treatment of glaucoma.

The present invention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety comprising prostaglandin analogues. The present invention also relates to methods for preparing the polymer conjugates using click chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the treatment of glaucoma.

A thermosetting resin composition comprises a component (A) that is a compound having an imide group and a carboxy group in one molecule, and a component (B) that is a polymer having a repeating unit represented by the following general formula (1). R.sup.1 and R.sup.2 in formula (1) are each independently a hydrogen atom or a methyl group. R.sup.3 in formula (1) is a hydrogen atom or any substituent, and a plurality of R.sup.3s may be bonded to form a ring structure. R.sup.4 in formula (1) is a hydrogen atom or an alkyl group. m and n in formula (1) are each independently an integer of 1 or more, and m/n may be 1 to 50. ##STR00001##

A thermosetting resin composition comprises a component (A) that is a compound having an imide group and a carboxy group in one molecule, and a component (B) that is a polymer having a repeating unit represented by the following general formula (1). R.sup.1 and R.sup.2 in formula (1) are each independently a hydrogen atom or a methyl group. R.sup.3 in formula (1) is a hydrogen atom or any substituent, and a plurality of R.sup.3s may be bonded to form a ring structure. R.sup.4 in formula (1) is a hydrogen atom or an alkyl group. m and n in formula (1) are each independently an integer of 1 or more, and m/n may be 1 to 50. ##STR00001##

A composition for manufacturing a semiconductor device includes at least one carbon-based compound that includes at least one of an alkyne group and an azide group, and a solvent. A method of manufacturing a semiconductor device includes forming a feature layer on a substrate, coating the feature layer with a composition including alkyne and azide, forming a carbon-containing layer including a triazole compound by performing a heat treatment on the coated composition, forming a photoresist film on the carbon-containing layer, forming photoresist patterns by exposing and developing the photoresist film, and patterning the carbon-containing layer and the feature layer using the photoresist patterns.

The present disclosure relates to a solid propellant composition for curing azide-alkyne triazole, which cures a propellant by forming a polymer network using triazole groups formed by a reaction between an azide compound and an alkyne compound, and a method for preparing a solid propellant using same.

The present disclosure relates to a solid propellant composition for curing azide-alkyne triazole, which cures a propellant by forming a polymer network using triazole groups formed by a reaction between an azide compound and an alkyne compound, and a method for preparing a solid propellant using same.

A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I): (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable drug selected from prostaglandins, -blockers and mixtures thereof; L is a linker group group; and at least one co-monomer of Formula III III J represents a linking functional group, n is 2 to 8, preferably 3 to 8; Y comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched Ci to do alkylene, amino, ether, ester, amide, carbonate and carbamate; A may be the same or different at each occurrence and represents a group comprising a terminal functional group comprising an alkyne or an azide functionality, wherein said terminal functional group is complementary to the terminal functional group X of formula (I) providing triazole moieties from reaction of X and A. ##STR00001##

A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I): (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable drug selected from prostaglandins, -blockers and mixtures thereof; L is a linker group group; and at least one co-monomer of Formula III III J represents a linking functional group, n is 2 to 8, preferably 3 to 8; Y comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched Ci to do alkylene, amino, ether, ester, amide, carbonate and carbamate; A may be the same or different at each occurrence and represents a group comprising a terminal functional group comprising an alkyne or an azide functionality, wherein said terminal functional group is complementary to the terminal functional group X of formula (I) providing triazole moieties from reaction of X and A. ##STR00001##

The present disclosure belongs to the technical field of lithium-sulfur batteries, and discloses covalent triazine framework polymer nanosheets for cathode materials in lithium-sulfur batteries. The hexaazatriphenylenehexacarbonitrile monomer on the surface of sodium chloride is polymerized through high temperature triazine, sodium chloride crystal is removed to obtain covalent triazine framework polymer nanosheets product, and cathode materials in lithium-sulfur batteries are obtained after melting sulfur. The preparation method of the present disclosure is simple, has low cost, high yield, and uniform structure. The obtained material itself has a porous structure and numerous active sites. When used in lithium-sulfur batteries, it can promote the rapid conversion of lithium polysulfides, effectively suppress the shuttle effect, and improve the rate performance and cycle performance of lithium-sulfur batteries.